{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:35:40Z","timestamp":1777581340428,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Posterior capsular opacification is treated using neodymium-doped yttrium aluminium garnet laser capsulotomy that leads to increased intraocular pressure. Here, we compare the effects of dorzolamide hydrochloride\u2009+\u2009timolol maleate versus brimonidine on intraocular pressure. We also investigate their side effects after neodymium-doped yttrium aluminium garnet laser capsulotomy. In these patients, there are no prior studies comparing the results of these two drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials<\/jats:title>\n                    <jats:p>\n                      Ninety patients with posterior capsule opacification contributed to the study. They received yttrium aluminium garnet laser capsulotomy. After yttrium aluminium garnet laser capsulotomy, they were randomized into three groups. Group 1 received dorzolamide hydrochloride\u2009+\u2009timolol maleate; Group 2 took brimonidine; and Group 3, the control group, took no drug. Group 1 took dorzolamide hydrochloride\u2009+\u2009timolol maleate eye drops 1\n                      <jats:bold>\u2005<\/jats:bold>\n                      h before the procedure and on the third hour of the first day and two times per day between the second and the seventh days. Group 2 took brimonidine eye drops 1\n                      <jats:bold>\u2005<\/jats:bold>\n                      h before the procedure and on the third hour of the first day, two times per day between the second and the seventh days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Brimonidine had a similar side effect profile to the fix combination. Intraocular pressure on the first (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.87) and third days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.124) were similar in Group 1 (dorzolamide hydrochloride\u2009+\u2009timolol maleate), Group 2 (brimonidine) and the control group. The mean intraocular pressure value of the control group was significantly higher than Groups 1 and 2 because the anti-glaucomatous effects of the drugs become prominent on the seventh day (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). In Group 1 and Group 2, intraocular pressure was significantly lower than the control group on the seventh day (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). Stinging, itching, hyperemia and Tyndall rates were similar in Group 1, Group 2 and the control group. Watery eyes were less common in the brimonidine group than in the dorzolamide hydrochloride\u2013timolol maleate and the control groups on the seventh day (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Brimonidine also significantly lowered the chemosis rate on the third (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and seventh (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We suggest that brimonidine and a combination of dorzolamide\u2009+\u2009timolol are similarly effective at reducing eye pressure for routine cases. In cases where intraocular pressure attacks might be at higher risk, using the dorzolamide\u2009+\u2009timolol combination would be more appropriate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721211052163","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:46:54Z","timestamp":1637214414000},"page":"2928-2934","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing the effects and safety of dorzolamide hydrochloride\u2009+\u2009timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification"],"prefix":"10.1177","volume":"32","author":[{"given":"Kaan","family":"\u00c7akmak","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, D\u00fczce State Hospital, D\u00fczce, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Erbil","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Goztepe Training and research Hospital, \u0130stanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Mesci","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kavac\u0131k Hospital, \u0130stanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eafak","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, D\u00fczce State Hospital, D\u00fczce, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-007-9101-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1988.01060130824031"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.176"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.03.006"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0092"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.4097\/kja.19049"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(00)00855-5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100050113040"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14757"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.09.022"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1544241"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-20000701-09"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-007-9101-6"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.176"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01525-5"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160411003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.25.4.237.13484"},{"key":"e_1_3_2_19_2","first-page":"14","article-title":"Apraclonidine versus brinzolamide - timolol combination to prevent intraocular pressure elevation after laser capsulotomy","volume":"16","author":"\u00c7elik E","year":"2016","unstructured":"\u00c7elik E, Altun G, Alagoz G. Apraclonidine versus brinzolamide - timolol combination to prevent intraocular pressure elevation after laser capsulotomy. Guoji Yanke Zazhi (Int Eye Sci) 2016; 16: 14\u201318.","journal-title":"Guoji Yanke Zazhi (Int Eye Sci)"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0146"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081-597X-20060901-16"},{"key":"e_1_3_2_22_2","first-page":"7","article-title":"Nd:yAG laser arka kapsulotomi sonras\u0131 g\u00f6z i\u00e7i bas\u0131n\u00e7 art\u0131\u015f\u0131n\u0131n at\u0131\u015f say\u0131s\u0131, at\u0131\u015f enerjisi ve toplam enerji ile ili\u015fkisi","volume":"28","author":"Cumurcu T","year":"2006","unstructured":"Cumurcu T, Etikan I. Nd:yAG laser arka kapsulotomi sonras\u0131 g\u00f6z i\u00e7i bas\u0131n\u00e7 art\u0131\u015f\u0131n\u0131n at\u0131\u015f say\u0131s\u0131, at\u0131\u015f enerjisi ve toplam enerji ile ili\u015fkisi. Erciyes T\u0131p Derg 2006; 28: 7\u201312.","journal-title":"Erciyes T\u0131p Derg"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0b013e3180587e0a"},{"key":"e_1_3_2_24_2","volume-title":"Cosopt (dorzolamide hydrochloride\/timolol maleate) [prescribing information]","unstructured":"Cosopt (dorzolamide hydrochloride\/timolol maleate) [prescribing information]. Lake Forest, IL: Akorn Inc, November 2020."}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721211052163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721211052163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721211052163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:45:06Z","timestamp":1777405506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721211052163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1177\/11206721211052163"],"URL":"https:\/\/doi.org\/10.1177\/11206721211052163","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}